LWCFA
OCUL icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Ocular Therapeutix OCUL Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.7K Buy
+7,500
New +$68K ﹤0.01% 407
2019
Q2 		– Sell
-20,000
Closed -$79K – 746
2019
Q1 		$79K Buy
20,000
+10,000
+100% +$40.2K ﹤0.01% 356
2018
Q4 		$40K Buy
+10,000
New +$55.1K ﹤0.01% 437

Other funds holding OCUL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's OCUL Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 7,500 shares worth $73.7K. The stake represents ﹤0.01% of the portfolio and ranks #407 among its holdings. This is a return to the name: Loring Wolcott & Coolidge Fiduciary Advisors previously reported a position in OCUL as recently as Q1 2019.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in OCUL in Q4 2018 and has held it in 3 quarters since. The position peaked at $79K in Q1 2019. 92 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Loring Wolcott & Coolidge Fiduciary Advisors held 7,500 shares of Ocular Therapeutix worth $73.7K as of Q2 2026.
  • Ocular Therapeutix was a new Loring Wolcott & Coolidge Fiduciary Advisors position in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #407 holding.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Ocular Therapeutix in Q4 2018 and has held it in 3 quarters since.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Ocular Therapeutix position peaked at $79K in Q1 2019.
  • 92 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.